In Brief: GSK consumer health up 4%, expansion costs hit P&G earnings, MJN faces headwinds, McKesson to take over Celesio
This article was originally published in The Tan Sheet
GSK consumer health climbs 4%; expansion costs hit P&G earnings; Mead Johnson faces headwinds despite high sales; Nu Skin has ‘tremendous’ Q3; McKesson to takeover Celesio; more In Brief.
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.